DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

SUMMARY: Notice is hereby given that the Office of Research Integrity (ORI) has taken final action in the following cases:

Terry S. Elton, Ph.D., The Ohio State University: Based on the reports of two investigations conducted by The Ohio State University (OSU) and additional analysis conducted by ORI in its oversight review, ORI found that Dr. Terry S. Elton, Professor, College of Pharmacy and Davis Heart and Lung Research Institute, OSU, engaged in research misconduct in research supported by National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), grants R01 HL048848, R01 HL084498, and P01 HL70294. National Institute of Child Health and Human Development (NICHD), NIH, grant R21 HD058997, National Institute on Aging (NIAID), NIH, grant R01 AG021912, National Institute of Allergy and Infectious Diseases (NIAID), NIH, grant R01 AI39963, and National Eye Institute (NEI), NIH, grant R01 EY012241.

ORI found that the Respondent engaged in research misconduct by falsifying and/or fabricating data that were included in 1 R21 HD058997–01, 1 R21 HD058997–01A1, 1 R21 HD058997–01A2, 1 RC1 HL100298–01, and in:


As a result of its investigation, OSU has recommended that all of the above publications be retracted.

Specifically, ORI finds that Respondent:

- Falsified and/or fabricated Western blots in an NIH grant application in three submissions of the same grant application:
  - Figures 4, 7, 11C: 1 R21 HD058997–01
  - Figures 7B, 7E, 8B: 1 R21 HD058997–01A
  - Figures 3C, 3F, 6C: 1 R21 HD058997–01A
  - and false Western blots were also included in Figure 6 in grant application 1 RC1 HL100298–01.
  - Falsified and/or fabricated Western blots in eighteen (18) figures and in six (6) published papers. Specifically false and/or fabricated images were included in:
    - Figure 6: J Biol Chem 282(33):24262–9, 2007 Aug 17
    - Figure 6: Mol Cell Endocrinol 249(1–2):21–31, 2006 Apr 25

Dr. Elton has entered into a Voluntary Exclusion Agreement and has voluntarily agreed:

1. To exclude himself from any contracting or subcontracting with any agency of the United States Government and from eligibility or involvement in nonprocurement programs of the United States Government referred to as “covered transactions” pursuant to HHS’ Implementation (2 CFR part 376 et seq.) of OMB Guidelines to Agencies on Governmwide Debarment and Suspension, 2 CFR part 180 (collectively the “Debarment Regulations”) for a period of three (3) years, beginning on November 26, 2012;

2. To exclude himself voluntarily from serving in any advisory capacity to PHS including, but not limited to, service on any PHS advisory committee, board, and/or peer review committee, or as a consultant for a period of three (3) years, beginning on November 26, 2012; and

3. To request that the following publications be retracted:

FOR FURTHER INFORMATION CONTACT:

Director, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 453–8200.

John E. Dahlberg,
Deputy Director, Office of Research Integrity.
[FR Doc. 2012–30866 Filed 12–21–12; 8:45 am]

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Public Meeting of the Presidential Commission for the Study of Bioethical Issues

AGENCY: Department of Health and Human Services, Office of the Assistant Secretary for Health, Presidential Commission for the Study of Bioethical Issues.

ACTION: Notice of meeting.

SUMMARY: The Presidential Commission for the Study of Bioethical Issues (the Commission) will conduct its twelfth meeting in January. At this meeting, the Commission will continue discussing topics related to the ethical issues associated with the development of medical countermeasures for children.

The draft meeting agenda and other information about the Commission, including information about access to the webcast, will be available at www.bioethics.gov.

The Commission welcomes input from anyone wishing to provide public comment on any issue before it. Respectful debate of opposing views and active participation by citizens in public exchange of ideas enhances overall public understanding of the issues at hand and conclusions reached by the Commission. The Commission is particularly interested in receiving comments and questions during the meeting that are responsive to specific sessions. Written comments will be accepted at the registration desk and comment forms will be provided to members of the public in order to write down questions and comments for the Commission as they arise. To accommodate as many individuals as possible, the time for each question or comment may be limited. If the number of individuals wishing to pose a question or make a comment is greater than can reasonably be accommodated during the scheduled meeting, the Commission may make a random selection.

Anyone planning to attend the meeting who needs special assistance, such as sign language interpretation or other reasonable accommodations, should notify Esther Yoo by telephone at (202) 233–3960, or email at Esther.Yoo@bioethics.gov in advance of the meeting. The Commission will make every effort to accommodate persons who need special assistance.